EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Challenges and Possible Strategies to Address Them in Rare Disease Drug Development: A Statistical Perspective

Jie Chen iD, Lei Nie iD, Shiowjen Lee, Haitao Chu iD, Haijun Tian, Yan Wang, Weili He iD, Thomas Jemielita iD, Susan Gruber iD, Yang Song iD, Roy Tamura, Lu Tian und 4 weitere

Clinical Pharmacology & Therapeutics · 2025-07 · 118 (1) · 62-73

DOI: 10.1002/cpt.3631 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 13.03.2025. Verfasst von Jie Chen und 15 weiteren Autor:innen. Beteiligte Einrichtung: ECR Global, Shanghai, China. Hauptthemen laut MEDLINE: Rare Diseases, Drug Development, Orphan Drug Production. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 100 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Developing drugs for rare diseases presents unique challenges from a statistical perspective. These challenges may include slowly progressive diseases with unmet medical needs, poorly understood natural history, small population size, diversified phenotypes and genotypes within a disorder, and lack of appropriate surrogate endpoints to measure clinical benefits. The Real‐World Evidence (RWE) Scientific Working Group of the American Statistical Association Biopharmaceutical Section has assembled a research team to assess the landscape including challenges and possible strategies to address these challenges and the role of real‐world data (RWD) and RWE in rare disease drug development. This paper first reviews the current regulations by regulatory agencies worldwide and then discusses in more detail the challenges from a statistical perspective in the design, conduct, and analysis of rare disease clinical trials. After outlining an overall development pathway for rare disease drugs, corresponding strategies to address the challenges are presented. Other considerations are also discussed for generating relevant evidence for regulatory decision‐making on drugs for rare diseases. The accompanying paper discusses how RWD and RWE can be used to improve the efficiency of rare disease drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rare DiseasesDrug DevelopmentOrphan Drug ProductionHumansClinical Trials as TopicResearch DesignDrug Approval

Autor:innen und Institutionen

  • ECR Global, Shanghai, China.
  • US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Pfizer Inc, Groton, Connecticut, USA.
  • Eli Lilly & Co., Indianapolis, Indiana, USA.
  • AbbVie, North Chicago, Illinois, USA.
  • Merck & Co., Inc., Rahway, New Jersey, USA.

ORCID-Profile: Jie Chen, Lei Nie, Haitao Chu, Weili He, Thomas Jemielita, Susan Gruber, Yang Song, Mark van der Laan, Hana Lee

Zitieren

APA

Chen, J., Nie, L., Lee, S., Chu, H., Tian, H., Wang, Y., He, W., Jemielita, T., Gruber, S., Song, Y., Tamura, R., Tian, L., Zhao, Y., Chen, Y., van der Laan, M., & Lee, H. (2025). Challenges and Possible Strategies to Address Them in Rare Disease Drug Development: A Statistical Perspective. Clinical Pharmacology & Therapeutics, 118(1), 62-73. https://doi.org/10.1002/cpt.3631

Vancouver

Chen J, Nie L, Lee S, Chu H, Tian H, Wang Y, et al. Challenges and Possible Strategies to Address Them in Rare Disease Drug Development: A Statistical Perspective. Clinical Pharmacology & Therapeutics. 2025;118(1):62-73. doi:10.1002/cpt.3631

BibTeX
@article{Chen2025,
  author = {Chen, Jie and Nie, Lei and Lee, Shiowjen and Chu, Haitao and Tian, Haijun and Wang, Yan and He, Weili and Jemielita, Thomas and Gruber, Susan and Song, Yang and Tamura, Roy and Tian, Lu and Zhao, Yihua and Chen, Yong and van der Laan, Mark and Lee, Hana},
  title = {Challenges and Possible Strategies to Address Them in Rare Disease Drug Development: A Statistical Perspective},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {118},
  number = {1},
  pages = {62--73},
  doi = {10.1002/cpt.3631}
}
Kostenlos starten →